Premium
Comparison of 5‐year outcomes of paclitaxel‐eluting and endeavor zotarolimus‐eluting stents in New York
Author(s) -
Qian Feng,
Zhong Ye,
Hannan Edward L.
Publication year - 2018
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27000
Subject(s) - medicine , hazard ratio , percutaneous coronary intervention , conventional pci , zotarolimus , confidence interval , cardiology , myocardial infarction , proportional hazards model , stent , propensity score matching , drug eluting stent , surgery
Objectives To evaluate long‐term outcomes in patients undergoing either paclitaxel‐eluting stents (PES) or endeavor zotarolimus‐eluting stents (E‐ZES) placement and to assess comparative effectiveness of PES vs. E‐ZES in different “off‐label” and “high‐risk” patient subgroups. Background PES and E‐ZES are frequently used in percutaneous coronary interventions (PCIs). However, the long‐term comparative effectiveness of PES vs. E‐ZES in real practice is unknown. Methods We created a longitudinal database by linking the New York State (NYS) cardiac registries, the NYS hospital discharge file, the National Death Index, and the U.S. Census file for patients undergoing either PES or E‐ZES placement from July 2008 through December 2009. All‐cause mortality, acute myocardial infarction (AMI), target lesion PCI (TLPCI), and target vessel coronary artery bypass graft (TVCABG) surgery were compared for 9,264 propensity score matched patients for a 5‐year follow‐up period using the Kaplan‐Meier method with further adjustment using Cox proportional hazards regression. Results We did not detect significant differences between E‐ZES and PES (reference) in 5‐year mortality (adjusted hazard ratio : 1.02, 95% confidence interval : 0.91–1.14), AMI (AHR: 1.05, 95% CI: 0.90–1.22), TLPCI (AHR: 0.99, 95% CI: 0.86–1.13), and TVCABG (AHR, 1.07, 95% CI: 0.84–1.36). For six “off‐label” and two “high‐risk” subpopulations, we had similar findings for the two stent groups. Conclusion NYS observational data suggest that 5‐year outcomes are comparable in patients receiving either PES or E‐ZES placement, mirroring the findings of recent clinical trials. © 2017 Wiley Periodicals, Inc.